Indianapolis division is drag on Roche profit

Roche Diagnostics operating income plummeted 21 percent last year, to $1.1 billion, as expiring patents crimped royalties and costs to launch new products increased, its Swiss parent, Roche Holding AG, reported today.

The Indianapolis-based division, which is a leader in blood-sugar test kits, limited the parent company’s overall increase in profit to 33 percent, or $6.35 billion, less than analysts expected, according to Bloomberg. Roche does not report quarterly financial performance.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}